Linezolid and tedizolid are associated with potentially severe adverse effects like serotonin syndrome and myelosuppression, which are often concentration-dependent and may be mitigated by therapeutic drug monitoring.
Understanding the risk factors and incidence of oxazolidinone-associated adverse effects, alongside therapeutic drug monitoring, can empower clinicians to safely utilize linezolid and tedizolid and facilitate intravenous to oral transitions.
Oxazolidinone antibiotics-linezolid and tedizolid-are often used to treat multidrug-resistant infections. They are highly bioavailable and ideal for transition to enteral therapy when appropriate. However, multiple associated adverse effects are potentially treatment-limiting. The objective of this review is to discuss relevant adverse effects of linezolid and tedizolid, including serotonin syndrome, myelosuppression, neuropathies, and lactic acidosis, and their commonality in real-world experience in the last decade. Mitigation strategies, including the role of therapeutic drug monitoring, are also discussed.
Greenfield et al. (Wed,) conducted a review in Bacterial infections requiring oxazolidinone antibiotics. Linezolid and tedizolid was evaluated on Incidence and risk factors of adverse effects (serotonin syndrome, myelosuppression, neuropathies, lactic acidosis). Linezolid and tedizolid are associated with potentially severe adverse effects like serotonin syndrome and myelosuppression, which are often concentration-dependent and may be mitigated by therapeutic drug monitoring.